Plain-English translation of NCT06263361 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a specialized approach to brain biopsy—using advanced MRI imaging combined with fluorescein sodium fluorescence—can help doctors diagnose primary central nervous system lymphoma more safely and accurately. Primary central nervous system lymphoma is a rare cancer that starts in the brain or spinal cord. The goal is to improve how doctors collect tissue samples from deep areas of the brain that are difficult to reach.
Currently, diagnosing this rare brain cancer is very challenging, especially when the tumor is located in deep parts of the brain. This trial aims to find better ways to safely biopsy these hard-to-reach areas so patients can get an accurate diagnosis and the right treatment more quickly.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would undergo a stereotactic biopsy—a specialized procedure where doctors use advanced MRI imaging to guide a needle to collect a tiny sample of brain tissue. During the procedure, your doctors will use the advanced imaging patterns and fluorescein dye to help them reach the right spot safely. The specific visits and follow-up care would be discussed with the research team, but the main focus is on improving the accuracy and safety of this diagnostic procedure.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Italy
Sponsor
IRCCS San Raffaele
Enrollment target
~15 participants
Started
October 2021
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Laura Sincinelli
IRCCS San Raffaele Scientific Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.